Rational Design of Doravirine: From Bench to Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rational Design of Doravirine: From Bench to Patients

Published:2019-10-17 Issue:1 Volume:6 Page:64-73
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Hwang Carey¹,Lai Ming-Tain¹,Hazuda Daria¹^ORCID

Affiliation:

1. Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

Funder

Merck Sharp and Dohme

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.9b00178

Reference69 articles.

1. Antiviral drug discovery and development: Where chemistry meets with biomedicine

2. Boehringer Ingelheim Pharmaceuticals, Inc. (2018) VIRAMUNE (nevirapine): prescribing information, Ridgefield, CT.

3. Delavirdine gets FDA approval. Food and Drug Administration. AIDS Alert 1997, 12 (6), 70.

4. Bristol-Myers Squibb Company. (2017) SUSTIVA (efavirenz): prescribing information, Princeton, NJ.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials;The Lancet HIV;2024-02

2. Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2-d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants;Acta Pharmaceutica Sinica B;2023-11

3. Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles;Journal of Medicinal Chemistry;2023-05-31

4. N-Phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor;Journal of Medicinal Chemistry;2023-05-02

5. Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors;Journal of Medicinal Chemistry;2022-02-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3